Regulatory submission for Sandoz’ proposed biosimilar pegfilgrastim accepted by FDA
Proposed biosimilar pegfilgrastim filing is the second of ten regulatory filings planned over the next three years Sandoz, a…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Novartis
Kenya launches ‘Novartis Access’
Agreements signed with Kenyan government and NGOs include programmes to distribute medicines, raise disease awareness and…
Novartis launches access programme for 15 medicines
Novartis Access to be launched first in Kenya, Ethiopia and Vietnam Novartis has launched Novartis Access, a portfolio of 15…
Sandoz launches Zarxio, the first biosimilar in US
Sandoz One Source, a patient services centre, was also launched Zarxio by Sandoz, a Novartis company, is now available in the US.…
Novartis in global partnership with Amgen
To develop and commercialise pioneering neuroscience treatments Novartis has entered into a global collaboration with Amgen to…
Novartis with WHO to work together to eliminate leprosy, sign five year agreement
Novartis Foundation's new leprosy contact tracing programme launched in five countries
US FDA approves Novartis’ eltrombopag
The approval was based on two randomised, double-blinded, placebo-controlled trials enrolling paediatric patients with chronic ITP…
Novartis acquires all remaining rights to GSK’s Ofatumumab
To develop treatments for MS and other autoimmune indications
Pfizer India to shut down Thane plant from September 16
Sandoz India's Turbhe plant to down shutters by December 2016
New data fuel hopes for broad use of Novartis psoriasis drug
Novartis is increasingly confident about the potential of its new injectable drug Cosentyx, as fresh clinical data confirms its…